LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE
American: KAPA), a clinical-stage biopharmaceutical company, announced today
that John S. Yu, M.D., Chief Executive Officer, will present a corporate
overview at the LD Micro Main Event XVII. The conference is being held on
October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
|
Event:
|
LD Micro Main Event XVII
|
| Presentation Date: |
Wednesday, October 30, 2024 |
| Time: |
12:00 PM PT |
| Presentation |
Click here
|
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is
at the forefront of oncology therapeutics, utilizing structural biology to
overcome drug resistance and immune suppression in cancer. Our lead candidate,
ENV105, is an antibody that targets CD105—a protein identified as a key driver
of resistance to various cancer treatments. Elevation of CD105 in response to
standard therapy results in resistance and disease relapse. ENV105 aims to
reverse drug resistance by targeting CD105 and restore the effectiveness of
standard therapies across multiple cancer types. Currently, ENV105 is in a
Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1
trial for lung cancer, addressing significant unmet medical needs. For more
information, visit
kairospharma.com.
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995. You can identify
forward-looking statements as those that are not historical in nature,
particularly those that use terminology such as “may,” “should,” “expects,”
“anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,”
“predicts,” “potential” or “hopes” or the negative of these or similar terms.
The reader is cautioned not to rely on these forward-looking statements. If
underlying assumptions prove inaccurate, or known or unknown risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections of Kairos Pharma. We base these forward-looking
statements on our expectations and projections about future events, which we
derive from the information currently available to us. Such forward-looking
statements relate to future events or our future performance. In evaluating
these forward-looking statements, you should consider various factors,
including: our expectations regarding the success and/or completion of our
Phase 1 and Phase 2 clinical trials; our success in completing newly initiated
clinical trials, commence new trials, and obtain regulatory approval following
the conclusion of such trials; challenges and uncertainties inherent in
product research and development; and the uncertainty regarding future
commercial success. These and other factors may cause our actual results to
differ materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking statements discussed in
this press release and other statements made from time to time by us or our
representatives, may not occur, and actual events and results may differ
materially and are subject to risks, uncertainties and assumptions about us,
including those described in Kairos Pharma’s prospectus filed with the SEC. We
are not obligated to publicly update or revise any forward-looking statement,
and Kairos Pharma is not required to update any forward-looking statement as a
result of new information or future events or developments, except as required
by U.S. federal securities laws.
Contact:
CORE IR
Louie Toma
investors@kairospharma.com
Source: Kairos Pharma, Ltd.